Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
florensocatib
- Development stage
- Phase 3
- Lead developer
- Chiesi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Florensocatib (CHF10196) is an oral small molecule inhibitor of dipeptidyl peptidase 1 (DPP1), also known as cathepsin C, currently in Phase III clinical development by Chiesi Farmaceutici. DPP1 is a lysosomal cysteine protease responsible for the activation of neutrophilic serine proteases (NSPs), including neutrophil elastase, proteinase 3, and cathepsin G, during neutrophil maturation in the bone marrow. In patients with non-cystic fibrosis bronchiectasis (NCFB), excessive NSP activity in the airways drives chronic inflammation, mucus hypersecretion, and progressive lung damage. By inhibiting DPP1, florensocatib prevents the activation of these pro-inflammatory proteases, thereby reducing airway inflammation and the frequency of pulmonary exacerbations. The drug is being evaluated in large-scale clinical trials, such as the FABLE study, to assess its efficacy and safety in both adult and adolescent populations.
- Other names
- florensocatib
02
Targets
CTSC (DPP1)
Beyond the preview
Go deeper on florensocatib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on florensocatib.